SUBSCRIBE
Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2007, Vol. 5 ›› Issue (2): 137-140.doi: 10.3736/jcim20070207

• Original Clinical Research • Previous Articles     Next Articles

Treatment of β-thalassemia with Bushen Yisui therapy: a randomized controlled trial

Zhi-kui Wu1, Yong-mei Liu1, Xin-hua Zhang2, Wen-jun Liu1, Min Li1, Rong-xin Wang2, Li-min Chai1, Wen-juan Wang1, Chong Zhang1, You-wen Huang2, Yu-ying Chen1, Xin-xia LV2   

  1. 1. Department of Molecular Biology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
    2. Department of Haematology, 303 Hospital of People's Liberation Army of China, Nanning, Guangxi Zhuang Autonomous Region 530021, China
  • Online:2007-03-31 Published:2007-03-15

RichHTML

0

PDF (PC)

94

Like

Objective: To investigate the efficacy and safety of Yisui Shengxue Granule (YSSXG), a compound traditional Chinese herbal medicine, in treating β-thalassemia. 

Methods: A randomized single-blinded trial was designed. Sixty patients with β-thalassemia were divided into two groups: 30 patients in YSSXG-treated group and 30 in placebo parallel-control group. The patients in the two groups were assigned to receive either YSSXG or placebo for three months. The patients' symptoms and their blood indexes such as hemoglobin (Hb), red blood cell (RBC), reticulocytes (Ret) and fetal hemoglobin (HBF) were examined before and after the treatment. Meanwhile, the liver and spleen were examined with B-mode ultrasound. 

Results: In the YSSXG-treated group, the blood indexes (Hb, RBC, Ret and HBF) and the symptoms of the patients were improved after three-month treatment, with statistical significance compared to those before treatment (P＜0.01); hepatauxe and splenomegaly were also relieved (P＜0.05) and no adverse reactions were monitored. In the placebo parallel-control group, no significant improvement of the blood indexes and symptoms, as well as the hepatauxe and splenomegaly had been found (P>0.05). 

Conclusion: YSSXG demonstrates obvious clinical efficacy and no adverse reactions in treating β-thalassemia.

Key words: beta-thalassemia, traditional Chinese medicine, clinical trials, controlled

CLC Number: 

  • R285.6

Table 1

Changes of blood indexes in YSSXG-treated group and placebo group（ヌ±S）"

GroupnHb (g/L)RBC (×1012/L)Ret (%)HBF (%)
YSSXG-treated group22222
Before treatment3075.13±5.593.54±0.676.47±5.0337.19±23.32
After one-month treatment3082.27±7.54**3.84±0.65**8.38±7.25**40.99±24.36**
After two-month treatment3086.47±9.43**4.02±0.75**9.39±8.15**43.41±25.62**
After three-month treatment3087.87±0.10**4.01±0.83**9.48±8.08**43.05±25.17**
Placebo group22222
Before treatment3065.37±20.603.26±0.943.73±3.3445.64±27.01
After one-month treatment3064.20±20.333.22±0.903.95±3.5045.72±26.34
After two-month treatment3064.87±20.983.20±0.963.85±3.1646.07±26.46
After three-month treatment3065.17±21.213.27±0.984.01±3.2246.91±26.77

Table 2

Traditional Chinese symptom CRF scores in YSSXG-treated group and placebo group（ヌ±S）"

GroupnSallow complexionDizzinessPalpitationShortness of breathLassitudeAnorexia
YSSXG-treated group2222211
Before treatment303.9±1.51.9±1.72.5±1.62.8±1.63.1±1.61.2±1.6
After one-month treatment303.2±1.10.9±1.1*1.5±1.3*1.5±1.3*1.9±1.0*0.6±1.2
After two-month treatment302.9±1.1*0.8±1.6*1.2±1.4*1.3±1.4*1.7±1.1*0.5±1.0
After three-month treatment302.7±1.2*0.9±1.5*1.2±1.5*1.3±1.4*1.7±1.3*0.5±1.6
Placebo group2222222
Before treatment304.1±1.51.7±1.91.9±1.72.0±1.93.1±1.61.5±1.7
After one-month treatment303.8±1.61.8±1.91.6±1.71.8±2.02.7±1.61.0±1.6
After two-month treatment303.4±1.61.2±1.81.3±1.51.4±1.92.3±1.61.0±1.6
After three-month treatment303.4±1.51.3±1.81.3±1.51.2±1.92.2±1.60.8±1.4

Table 3

B-mode ultrasound examination results of liver and spleen in YSSXG-treated group and placebo group （ヌ±S, cm）"

GroupnLiver oblique diameterSpleen transverse diameter
YSSXG-treated group222
Before treatment2812.33±1.563.96±2.13
After three-month treatment2812.21±1.613.84±2.12*
Placebo group222
Before treatment2811.72±2.293.93±1.75
After three-month treatment2811.79±2.393.84±1.75
[1] 张之南. 血液病诊断及疗效标准[M].北京: 科学出版社,1998.48
Zhang ZN.Standard of diagnosis and therapeutic effect of hematop[M].Beijing: Science Press,1998.48
[2] Cao A, Galanello R, Rosatelli MC, et al.Clinical experience of management of thalassemia: the Sardinian experience[J].Semin Hematol,1996,33(1):66-75
[3] 中华人民共和国卫生部. 中药新药临床研究指导原则. 第2辑. 1995: 137-138.
Ministry of Health of the People's Republic of China. Guiding principle of clinical research on new drugs (Part 2). 1995: 137-138. Chinese.
[4] 沈自尹, 王文健.中医虚证辨证参考标准[J].中西医结合杂志,1986,6(10):598
Shen ZY, Wang WJ.Reference criteria for differentiation of deficiency syndromes in traditional Chinese medicine[J].Zhong Xi Yi Jie He Za Zhi,1986,6(10):598
[5] 吴志奎, 蔡辉国, 陈佩贞, 等.补肾生血方对β-地中海贫血基因水平的影响[J].中医杂志,1997,38(2):91-93
Wu ZK, Cai HG, Chen PZ, et al.Effect of Bushen Shengxue recipe on β-mediterranean anemia in gene level[J].Zhong Yi Za Zhi,1997,38(2):91-93
[6] Wu ZK.Clinical efficiency and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia[J].Chin J Integr Med,2003,9(4):248-253
[7] 吴志奎, 张新华, 王蕾, 等.益髓生血灵治疗β-地中海贫血92例临床研究[J].中国中医药信息杂志,2004,11(4):292-294
Wu ZK, Zhang XH, Wang L, et al.Clinical study on treatment effect of compound Yisui Shengxueling for 92 cases of β-thalassemia[J].Zhongguo Zhong Yi Yao Xin Xi Za Zhi,2004,11(4):292-294
[1] Chiung-Hui Huang, Mei-Ling Yeh, Fang-Pey Chen, Daphne Wu. Low-level laser acupuncture reduces postoperative pain and morphine consumption in older patients with total knee arthroplasty: A randomized placebo-controlled trial. Journal of Integrative Medicine, 2022, 20(4): 321-328.
[2] Wan-jun Guo, Yi Wang, Yu Deng, Lin-yan Cheng, Xin Liu, Ruo-fan Xi, Sheng-jie Zhu, Xin-yi Feng, Liang Hua, Kan Ze, Jian-yong Zhu, Dong-jie Guo, Fu-lun Li. Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, 20(4): 376-384.
[3] Shang-jin Song, Xuan Liu, Qing Ji, Da-zhi Sun, Li-juan Xiu, Jing-yu Xu, Xiao-qiang Yue. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression. Journal of Integrative Medicine, 2022, 20(4): 355-364.
[4] Maryam Azimi, Hanieh Niayesh, Mahboobeh Raeiszadeh, Sedigheh Khodabandeh-shahraki. Efficacy of the herbal formula of Foeniculum vulgare and Rosa damascena on elderly patients with functional constipation: A double-blind randomized controlled tria. Journal of Integrative Medicine, 2022, 20(3): 230-236.
[5] Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Ana Elisa Madureira Padula, Livia Mitchiguian Hotta, Amarilysde Toledo Cesar, José Nelson Martins Diniz, Helen de Freitas Santos, Edson Zangiacomi Martinez. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). Journal of Integrative Medicine, 2022, 20(3): 221-229.
[6] Marisa Casal. Improving the health and treatment success rates of in vitro fertilization patients with traditional chinese medicine: need for more robust evidence and innovative approaches. Journal of Integrative Medicine, 2022, 20(3): 187-192.
[7] Ning Guo, Fei Wu, Mei Wu, Yuan Wang, Qing Lang, Xiao Lin, Yi Feng. Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine . Journal of Integrative Medicine, 2022, 20(3): 204-212.
[8] Xin Wang, Wen-juan Song, Yi Ruan, Bing-chu Li, Can Lü, Nian Huang, Fan-fu Fang, Wei Gu. Core muscle functional strength training for reducing the risk of low-back pain in military recruits: An open-label randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 145-152.
[9] Yan-jun Lin, Kun-li Jiao, Bo Liu, Lu Fang, Shu Meng. Antiplatelet and myocardial protective effect of shexiang tongxin dropping pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 126-134.
[10] Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[11] Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[12] Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[13] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[14] Ning Zhang, Xiao-he Xiao. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. Journal of Integrative Medicine, 2021, 19(4): 291-294.
[15] Thomas Efferth, An-long Xu, Roxana Damiescu, Mita Banerjee, Norbert W. Paul, David Y.W. Lee. Can eastern wisdom resolve western epidemics? Traditional chinese medicine therapies and the opioid crisis. Journal of Integrative Medicine, 2021, 19(4): 295-299.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2] Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3] Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5] Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7] Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8] Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9] Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10] Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239
Journal of Integrative Medicine, ISSN: 2095-4964 CN 31-2083/R
Copyright © Journal of Integrative Medicine
Powered by Beijing Magtech Co. Ltd
沪公网安备31010602003416号      沪ICP备18017633号-3